JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lardinois, D.
Right arrow Articles by Weder, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lardinois, D.
Right arrow Articles by Weder, W.
Related Collections
Right arrow Lung - cancer
Right arrow Pleura
Right arrow Chest wall

J Thorac Cardiovasc Surg 2006;131:697-703
© 2006 The American Association for Thoracic Surgery

General Thoracic Surgery

Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma

D. Lardinois, MD a , * , F.J. Jung, MD a , I. Opitz, MD a , K. Rentsch, MD b , C. Latkoczy, MD c , V. Vuong, PhD d , Z. Varga, MD e , V. Rousson, PhD f , D. Günther, MD c , S. Bodis, MD d , R. Stahel, MD g , W. Weder, MD a

a Division of Thoracic Surgery, University Hospital, Zurich, Switzerland
b Institute of Clinical Chemistry, University Hospital, Zurich, Switzerland
d Department of Radiation Oncology, University Hospital, Zurich, Switzerland
e Institute of Clinical Pathology, University Hospital, Zurich, Switzerland
f Institute of Biostatistics, University Hospital, Zurich, Switzerland
g Division of Oncology, University Hospital, Zurich, Switzerland
c Laboratory of Inorganic Chemistry, ETH, Zurich, Switzerland

Received for publication June 2, 2005; revisions received August 5, 2005; accepted for publication August 17, 2005.

* Address for reprints: D. Lardinois, MD, Division of Thoracic Surgery, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland. (Email: didier.lardinois{at}usz.ch).

OBJECTIVE: We sought to investigate whether intrapleural topical application of cisplatin with a surgical carrier has a prolonged local tissue level in comparison with cisplatin solution while reducing systemic toxicity.

METHODS: Forty immune-competent Fischer rats were inoculated with 106 mesothelioma cells. Ten days later, left pneumonectomy with tumor debulking was performed. Twenty animals underwent local application of cisplatin solution (100 mg/m2), whereas the same quantity of cisplatin was topically applied as a gel with the Vivostat (Vivolution) system in 20 other animals. In each group 5 subgroups of 4 animals were defined according to the harvesting time of blood and tissue samples (2, 4, 24, and 72 hours and 1 week) after local therapy. Platinum concentrations in serum and tissue and systemic toxicity were analyzed.

RESULTS: Platinum concentrations in tissue were significantly higher in the gel group (group 1) than in the solution group (group 2) at 1, 3, and 7 days after therapy (1510, 1224, and 1069 pg/mg for group 1 vs 598, 382, and 287 pg/mg for group 2; P = .007, P = .005, and P = .0002, respectively). Laboratory findings showed renal insufficiency in the animals of the solution group at 1 week, with values of 98 mmol/L versus 7.7 mmol/L for urea and 410 µmol/L versus 43 µmol/L for creatinine (P = .02 and P = .01, respectively), which was confirmed by means of pathologic analysis.

CONCLUSIONS: Intrapleural administration of cisplatin with the carrier Vivostat significantly provides sustained higher platinum concentrations up to 1 week in tissue in comparison with application of cisplatin solution without conferring systemic toxicity in this model.

Abbreviations and Acronyms PAS = periodic acid-Schiff




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
I. Opitz, B. V. Erne, S. Demirbas, A. Jetter, B. Seifert, R. Stahel, and W. Weder
Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: A preclinical study.
J. Thorac. Cardiovasc. Surg., January 1, 2011; 141(1): 65 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Cardiothorac SurgHome page
L. Ampollini, F. Sonvico, E. Barocelli, A. Cavazzoni, R. Bilancia, C. Mucchino, A. M. Cantoni, and P. Carbognani
Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study
Eur J Cardiothorac Surg, March 1, 2010; 37(3): 557 - 565.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. M. Rademakers, P. F. Grundeman, R. W. Bolderman, F. H. van der Veen, and J. G. Maessen
Stability of an autologous platelet clot in the pericardial sac: An experimental and clinical study.
J. Thorac. Cardiovasc. Surg., May 1, 2009; 137(5): 1190 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Cardiothorac SurgHome page
L. Ampollini, A. Soltermann, E. Felley-Bosco, D. Lardinois, S. Arni, R. F. Speck, W. Weder, and I. Opitz
Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting
Eur J Cardiothorac Surg, March 1, 2009; 35(3): 457 - 462.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. Zellos, W. G. Richards, L. Capalbo, M. T. Jaklitsch, L. R. Chirieac, B. E. Johnson, R. Bueno, and D. J. Sugarbaker
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 453 - 458.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Cardiothorac SurgHome page
I. Opitz, D. Lardinois, S. Arni, S. Hillinger, P. Vogt, B. Odermatt, V. Rousson, and W. Weder
Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment
Eur J Cardiothorac Surg, May 1, 2007; 31(5): 772 - 778.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.